YOLFTbeta
68

Jiangsu Hanbon Science and Technology Co., Ltd.

688755 · SHG · Healthcare / Medical Devices

24.30CNY-0.70 (-2.80%)

Price History

Full chart

Market Stats

Previous Close25.00
Open24.90
Day Range24.05 – 25.20
52-Week Range21.89 – 33.91
Volume1.35M
Market Cap2.72B
P/E (TTM)30.92
Forward P/E0.00
EPS0.77
Dividend Yield1.01%
50-Day Avg27.21
200-Day Avg28.09

About

Jiangsu Hanbon Science and Technology Co., Ltd. engages in the research and development, production, and sale of liquid chromatography products in China and internationally. It offers biopharm purification equipment, including chromatography column products, chromatography systems, buffer dilution/conditioning systems, filtration systems, and single-use systems; bio-oligo synthesizer products, such as nucleic acid synthesizer and oligonucleotide synthesis column products; and preparative liquid chromatography system and chromatographic column products. It also provides continuous chromatographic systems comprising simulated moving bed and continuous Ion exchange chromatography products; and supercritical fluid chromatography products, including analytical supercritical fluid chromatography, SFC-dynamic axial compression column, and CO2 booster station products. In addition, it offers biopharmaceutical purification, peptide purification, and small molecule purification solutions. The company was founded in 1998 and is based in Huai'an, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Da Bing Zhang
  • Employees716
  • HeadquartersNo.1-9 Jixian Road, Huai'an, China, 223005, China
  • Websitehttps://www.hanbon.com.cn

Leadership

  • Mr. Da Bing ZhangChairman & GM · b. 1969
  • Mr. Bin GuChief Finance Officer · b. 1972
  • Mr. Gen Shui LiuDeputy General Manager · b. 1981
  • Mr. Sheng Ying LiDeputy GM & Director · b. 1980
  • Mr. Ye Feng TangDeputy GM, Secretary of the Board of Directors & Director · b. 1978
  • Mr. Zhong YanDeputy GM · b. 1982
  • Mr. Xin Liang JinDeputy General Manager · b. 1982

Financials

Income Statement

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Total Revenue481.79M619.01M690.88M735.13M
Growth (%)-+28.48%+11.61%+6.40%
Cost of Revenue292.56M373.93M398.95M473.65M
Gross Profit189.24M619.01M291.93M261.48M
Gross Margin39.28%100.00%42.25%35.57%
Operating Expense123.91M0169.44M165.02M
Operating Income65.33M619.01M122.49M96.46M
Operating Margin13.56%100.00%17.73%13.12%
EBITDA57.97M71.68M110.57M86.53M
EBITDA Margin12.03%11.58%16.00%11.77%
Net Income38.56M51.50M79.34M59.65M
Net Income Margin8.00%8.32%11.48%8.11%
R&D28.99M37.18M45.32M45.29M
R&D as % of Total Revenue6.02%6.01%6.56%6.16%
Interest Expense2.89M4.37M3.21M209.43K
Interest Expense % of Total Revenue0.60%0.71%0.46%0.03%

Balance Sheet

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Total Assets1.40B1.35B1.32B1.94B
Total Liabilities837.08M714.93M585.19M695.81M
Total Equity566.92M638.37M739.63M1.24B
Cash480.26M497.30M473.18M750.75M

Cash Flow

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow19.84M113.33M129.88M122.42M
Capital Expenditure45.34M50.24M39.81M96.22M
Free Cash Flow-25.50M113.33M90.07M26.20M
Dividends Paid4.47M4.35M3.28M9.06M
FCF to OCF-128.57%100.00%69.35%21.40%
Dividend Paid to FCF-17.52%3.84%3.65%34.57%

Key Statistics & Ratios

Market Cap2.72B
Enterprise Value1.82B
Trailing P/E30.92
Forward P/E0.00
Price / Sales3.21
Price / Book2.14
EPS0.77
Book Value11.08
Revenue (TTM)849.02M
Gross Profit (TTM)269.68M
EBITDA99.59M
Profit Margin10.20%
Operating Margin26.50%
Return on Equity6.96%
Return on Assets2.59%
Shares Outstanding114.40M
Shares Float63.58M
Dividend Yield1.01%
Dividend Rate0.24
Payout Ratio15.69%